Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...

A mother and son from Georgia recently visited Kentucky for the first time. What drew them in, they say, was the ...

Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne ...

Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531.

The stock is trading at $8.18, up $2.84, gaining 53.18% on volume of over 12.4 Million shares. The stock had a days' high of $8.33.

Goldman Sachs has initiated coverage on Avidity Biosciences with a Buy rating and a $59 price target, citing ...

Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular ...

“Grand Forks Fire displays an unwavering support for MDA year after year, raising critical funds and awareness to help our ...

Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a ...

Wave’s result is in line with the data that supported accelerated approval of NS Pharma’s exon 53 DMD drug Viltepso. NS ...

During a panel discussion at the National Society of Genetic Counselors meeting, genetic counselors discuss the risks and benefits of gene therapies.

Shares of Wave Life Sciences rose more than 10% in premarket trading Tuesday after the clinical-stage biotechnology company reported positive interim data from a mid-stage study of its WVE-N531 drug ...